Theriva Biologics Inc. (TOVX)
TOVX trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | TOVX on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000894158 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials
No annual revenue filed since the period ending 2011-12-31.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $8.5M cash; operating cash flow -$2.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 45,892,668 (2026-11-10); 33,739,643 a year earlier; 17,042,765 three years earlier. 3y figure adjusted for splits (1-for-25 overall). | Cover page 2026-11-10 |
| Reverse splits, 3 years | 1; latest 1-for-25 on 2024-08-26 | Source 2024-08-26 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2025-12-03 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | BDO USA, P.C., Raleigh, North Carolina, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$1.5M | -$2.9M | $8.5M | $1.7M | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $0 | -$3.2M | -$3.1M | $11.3M | $1.7M | Needs four quarters | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $300K | -$2.0M | -$2.5M | $14.4M | $1.7M | Needs four quarters | 10-Q 2026-05-05 |
| Q4 2025 2025-12-31 | Not filed | -$2.0M | -$2.9M | $13.1M | $1.7M | Needs four quarters | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | Not filed | -$4.4M | -$4.3M | $7.5M | $1.8M | Needs four quarters | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | Not filed | -$13.1M | -$4.7M | $12.1M | $56K | Needs four quarters | 10-Q 2026-11-12 |
| Q1 2025 2025-03-31 | Not filed | -$4.3M | -$4.8M | $10.0M | $51K | Needs four quarters | 10-Q 2026-11-12 |
| Q4 2024 2024-12-31 | Not filed | -$4.4M | -$4.7M | $11.6M | $92K | Needs four quarters | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-03 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-12 |
| Latest current report FORM 8-K | 8-K | 2026-11-12 |
| Latest proxy | DEF 14A | 2026-10-20 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -17.6% |
| 1 month | -36.4% |
| 3 months | -39.1% |
| Year to date | -33.3% |
| 1 year | -50.0% |
| From 52-week high | -65.9% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ENVB | Enveric Biosciences Inc. | $1.44 | -4.95% | $6.4M |
| ADXN | Addex Therapeutics Ltd | $3.83 | -5.67% | $6.5M |
| TCRT | Alaunos Therapeutics Inc. | $1.60 | -1.84% | $6.7M |
| SNGX | Soligenix Inc. | $0.2882 | -10.22% | $6.7M |
| FBLG | FibroBiologics Inc. | $0.9034 | -2.00% | $6.1M |
| TPST | Tempest Therapeutics Inc. | $0.3418 | -10.50% | $6.8M |
| XCUR | Exicure Inc. | $1.07 | -0.93% | $7.0M |
| LTRN | Lantern Pharma Inc. | $0.3890 | -10.18% | $5.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier